数字肠导向CBT可能改善IBS中的便失禁
Sanskriti Varma1,2,3, Luisa L Scott4, Alice Sibelli4
1Division of Gastroenterology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114-2696, USA. sanskriti.varma@gmail.com.
Digestive diseases and sciences
|February 14, 2025
概括
一个基于应用程序的肠道导向认知行为疗法 (CBT) 计划显著减少了易肠综合征 (IBS) 患者的便失禁 (FI) 事件. 这种数字治疗有望改善IBS相关FI患者的生活质量.
科学领域:
- 胃肠病学 胃肠病学
- 数字治疗学数字治疗学
- 行为科学 行为科学
背景情况:
- 便失禁 (FI) 影响高达20%的刺激性肠综合征 (IBS) 患者,对生活质量产生负面影响.
- 数字认知行为疗法 (CBT) 为IBS相关FI提供了一个潜在的干预措施.
研究的目的:
- 评估基于应用程序的肠道导向CBT计划在减少IBS患者FI发作中的有效性.
- 分析真实世界的用户数据,以评估数字CBT对FI和症状严重性的影响.
主要方法:
- 从2021年8月到2024年2月使用数字CBT程序 (MahanaTM) 的66名IBS患者的回顾性分析.
- 混合效应线性回归模型被用于分析FI发作的变化和IBS症状严重性评分系统 (IBS-SSS) 在10次会议中的得分.
- 包括标准要求完成至少一个程序会话,症状日志条目,并报告至少一个FI事件.
主要成果:
- 平均IBS-SSS得分从基线 (286) 显著下降到第5次会议 (206) 和第10次会议 (193) (p < 0.0001).
- 每位用户平均FI发作数量从5 (会议1) 大幅下降到0.5 (会议5) 和0.1 (会议10) (p < 0.0001).
- 100%的患者完成了≥2次会议,在第一次和最后一次会议之间,FI发作减少了≥50%.
结论:
- 基于应用程序的肠导向数字CBT有效地减少了IBS相关FI的频率.
- 数字CBT干预措施显示了改善IBS治疗患者治疗结果的潜力.
- 需要进一步的研究来探索数字CBT在脑肠互动中的神经生理机制.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
145
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
145
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Irritable Bowel Syndrome I: Introduction
257
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
257
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
147
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
147
Irritable Bowel Syndrome III: Medical and Nursing Management
180
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
180
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
324
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
324


